
|Articles|May 25, 2018
Osteoporosis Drug Approval Highlights AJPB Week in Review
Author(s)AJPB staff
Top news of the week from The American Journal of Pharmacy Benefits.
Advertisement
5. FDA Grants Breakthrough Therapy, Fast Track Designations to Narcolepsy Treatment
The FDA has granted Harmony Biosciences a Breakthrough Therapy designation for pitolisant, an investigational therapy for the treatment of cataplexy in patients with narcolepsy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
IRAKLIA Trial Shows Body Weight Doesn’t Alter Outcomes With On-Body Injector Isatuximab
2
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
3
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5

















































































































































































































